XCUR

distress 5/10 · elevated risk

$1.75-1%today-80% from 52w high

exicuretx.com2 employeesFounded 2011Redwood City, CABiotechnology

Revenue

pre-revenue

Liquidity

$3M

Runway

0.3 yrs

Shares 1y

+1%

Price & events

-72.8% over 6M

CatalystRating changeDilutionFinancingdashed = today

-0.6%

+8.0%

-35.9%

-51.9%

-71.6%

-79.1%

-16.5%

-99.2%

-99.4%

All

Overview

Market Cap: $11.15M
Volume: 18.16K
52 Week Range: $1.62 – $8.86
Total Shares: 6.37M
Float Shares: 2.92M
Short %: 0.22%
% Held by Insiders: 32.81%
% Held by Institutions: 2.70%
RVOL: 0.02x
Beta: 3.60

Pipeline · 0 trials · 0 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
No pipeline trials tracked.

Catalyst news & presentations · 2

2026-01-16partnershipBurixafor (GPC-100) · Achieved first contractual milestone under License and Collaboration Agreement with GPCR Therapeutics: completion of Phase 2 trial and CSR submission to FDA.SEC 8-K
2024-12-24partnershipReceived $8.7M from closing of Common Stock Purchase Agreement with HiTron Systems Inc.SEC 8-K

Approved drugs (0)

none — clinical-stage

Capital structure — dilution & financing

Shares out: 6,373,937 · 1 offerings/1y · 0 PIPEs

2025-07-22424B3offering
2025-07-22EFFECTshelf_effective
2025-07-11S-1shelf_registration
2025-05-068-Kmaterial_agreement
2025-02-218-Kprivate_placement
2025-01-228-Kmaterial_agreement
2024-12-118-Kmaterial_agreement

🔒 Positioning — Pro

Short interest / days-to-cover, insider buys & sells.

Upgrade to Pro

🔒 Top holders — Pro

Institutional ownership + quarter-over-quarter accumulation/trimming.

Upgrade to Pro

Wall St ratings

no consensus

no recent rating changes

Competitors

none identified